Global and China Monoclonal Antibody Industry Report, 2013

Publisher Name :
Date: 1-Jan-2013
No. of pages: 100
Inquire Before Buying

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the global monoclonal antibody market scale will reach USD78 billion in 2012. Meanwhile, monoclonal antibody is also a key major source of blockbuster drugs. In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (Abbvie) and Trastuzumab (Roche) reached above USD5 billion around the globe, approximating 60% of global monoclonal antibody market.

Due to the features as high technical threshold, large capital demand and high rate of return, the international pharmaceutical giants (including Roche, Johnson & Johnson, Abbvie, Amgen, Novartis, etc.) are still accelerating the research and industrialization of monoclonal antibody agents through M&A or cooperation on the basis of existing monoclonal antibody products. For example, in April 2012, Amgen and AstraZeneca announced that they would jointly develop and sell the 5 monoclonal antibody agents of Amgen under research, namely, AMG827, AMG139, AMG181, AMG557 and AMG157.

Although the monoclonal antibody has witnessed rapid development, and the market scale is expected to share 8%-10% of world’s total in 2012, the market in China is still mainly occupied by imported products. As of the end of 2012, the number of imported monoclonal antibody products approved by SFDA amounted to 11, while that of domestic-made products only reached 8; the number of imported monoclonal antibody agents approved for clinical tests in China amounted to 27, while the figure of domestic products only hit 20, mainly imitating the overseas original drugs.

At present, the imported products as Rituximab, Trastuzumab, Cetuximab, Infliximab and Bevacizumab have contributed 70%-75% of monoclonal antibody market in China; the rest market is shared by the home-made drugs as Yisaipu®(Recombinant Human TNF Receptor-Ig Fusion Protein)and Xenopax® (Recombinant Humanized Anti-CD25 Monoclonal Antibody)of CPGJ, and Nimotuzomab of Biotech Pharma. Besides, several imported monoclonal antibody agents have accessed some local medical insurance systems. For example, Remicade®(Infliximab), which is used to treat rheumatoid, has accessed 11 local medical insurances, Simulect® (Bevacizumab, used in anti-transplant rejection) has accessed 10 local medical insurances, and Rituxan® (Rituximab, used to treat tumors) has accessed 9 local medical insurances. Meanwhile, since it may take 3-5 years for the domestic-made monoclonal antibody agents to achieve large scale and industrialized marketing, the imported markets will still embrace expectable development in future.

In view of the optimistic market prospect, advancement of monoclonal antibody technologies, support of favorable policies and the upcoming patent expiration of several key monoclonal antibody agents, multiple local enterprises as Hisun Pharmaceutical, Fosun Pharmaceutical, Walvax Biotechnology and SL Pharmaceutical are now marching into the monoclonal antibody market by huge capitals successively.

As of December 2012, the first monoclonal antibody generic drug (generic drug of enbrel) – Anbainuo® of Hisun Pharmaceutical was under phase III clinical supplementary test, and is expected to be approved by the end of 2013. The commercialized capacity will be 3.2 million pieces per year; furthermore, Enbrel has been tested in Brazil, etc., and is expected to achieve export.

In July 2012, the environmental impact assessment concerning phase I of new medicine pilot test base project (monoclonal antibody agents) of Fosun Pharmaceutical was publicized. According to the notice, the pilot scale of the project will be 130kg/a (equal to 1.3 million pcs/a of Rituximab), and the construction content involves raw material storage, pilot workshop, quality inspection, administration building and supporting public auxiliary facilities.

In April 2012, Walvax Biotechnology announced to jointly sign Cooperation Framework Agreement with Shanghai Fengmao Biotechnology, Shanghai Winlord Industries & Trading, and natural persons Wang Xiaofei and Kong Haiyan, planning to invest in Shanghai Fengmao in future four years, and research and industrialize Rituximab, Bevacizumab, Adalimumab, Panitumumab, Denosumab and long-acting EPO; in August, the company invested RMB246 million to establish the fully-owned subsidiary Shanghai Walvax, so as to promote the industrialization of the above six blockbuster bio-similar products. Nevertheless, according to the public information, the monoclonal antibody generic drugs of Walvax Biotechnology cannot be marketed until 2017 (Rituximab and Panitumumab as planned), and the commodity volume is expected to be 12kg/a, sharing 10% of planned capacity.

Global and China Monoclonal Antibody Industry Report, 2013 of ResearchInChina mainly involves the following contents:

  • Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry around the globe;
  • Development status, market scale, competitive pattern and development forecast, etc. of monoclonal antibody industry in China;
  • Operation, monoclonal antibody business, development in China, R&D status, etc. of 6 monoclonal antibody enterprises around the globe and 10 enterprises in China.

Global and China Monoclonal Antibody Industry Report, 2013

Table Of Contents

1. Overview of Monoclonal Antibody Industry
1.1 Definition
1.2 Classification
1.3 Technological Development

2. Development of Global Monoclonal Antibody Industry
2.1 Development Situation
2.2 Market Scale
2.3 Competitive Pattern
2.4 Development Prospect and Forecast
2.4.1 Market Scale Forecast
2.4.2 Competitive Pattern Forecast
2.4.3 R&D Tendency Prediction

3. Monoclonal Antibody Industry in China
3.1 Development Situation
3.2 Market Scale
3.3 Market Segments
3.3.1 Rituximab/Rituxan®
3.3.2 Trastuzumab/Herceptin®
3.3.3 Cetuximab/Erbitux®
3.3.4 Nimotuzumab
3.3.5 Bevacizumab
3.3.6 Recombinant Human TNF Receptor-Ig Fusion Protein for Injection
3.4 Competitive Pattern
3.5 Development Prospect

4. Key Enterprises of Monoclonal Antibody Agents Overseas
4.1 Roche Pharmaceuticals
4.1.1 Profile
4.1.2 Operation
4.1.3 R&D and Investment
4.1.4 Monoclonal Antibody Business (Genentech)
4.1.5 Business in China
4.2 Johnson & Johnson
4.2.1 Profile
4.2.2 Operation
4.2.3 R&D and Investment
4.2.4 Monoclonal Antibody Business
4.2.5 Business in China
4.3 Merck
4.3.1 Profile
4.3.2 Operation
4.3.3 R&D and Investment
4.3.4 Monoclonal Antibody Business
4.3.5 Business in China
4.4 NOVARTIS
4.4.1 Profile
4.4.2 Operation
4.4.3 R&D and Investment
4.4.4 Monoclonal Antibody Business
4.4.5 Business in China
4.5 AbbVie (Abbott)
4.5.1 Profile
4.5.2 Operation
4.5.3 R&D and Investment
4.5.4 Monoclonal Antibody Business
4.5.5 Business in China
4.6 Amgen
4.6.1 Profile
4.6.2 Operation
4.6.3 R&D and Investment
4.6.4 Monoclonal Antibody Business
4.6.5 Business in China

5. Key Enterprises of Monoclonal Antibody Agents in China
5.1 Shanghai Lansheng States Kin Pharmaceutical Co., Ltd.
5.1.1 Profile
5.1.2 Shanghai CP Guojian Pharmaceutical Co., Ltd.
5.1.3 Shanghai Zhangjiang Biotech Co., Ltd.
5.1.4 Shanghai CP GuoJian Biotech Academy
5.1.5 Shanghai Guosheng Pharmaceutical Co., Ltd.
5.2 Beijing Biotech Pharmaceutical Co., Ltd.
5.2.1 Profile
5.2.2 Competitive Edges
5.2.3 Development Prospect
5.3 Chengdu Huasun Group Co., Ltd.
5.3.1 Profile
5.3.2 Chengdu Huasun Biotech Co., Ltd.
5.4 Shanghai Medipharm Biotech Co., Ltd.
5.4.1 Profile
5.4.2 Monoclonal Antibody Business
5.5 Shanghai Yalian Antibody Pharmaceutical Co., Ltd.
5.5.1 Profile
5.5.2 Monoclonal Antibody Business
5.6 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.6.1 Profile
5.6.2 Monoclonal Antibody Business
5.7 Yunnan Walvax Biotechnology Co., Ltd.
5.7.1 Profile
5.7.2 Monoclonal Antibody Business
5.8 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
5.8.1 Profile
5.8.2 Monoclonal Antibody Business
5.9 Beijing SL Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Monoclonal Antibody Business
5.10 Shenzhen Main Luck Pharmaceuticals Inc.
5.10.1 Profile
5.10.2 Monoclonal Antibody Business

List Of Charts

Composition of Monoclonal Antibody Agents Worldwide by Type, 2011
Technological Level of Monoclonal Antibody Agents in Developed Countries of Europe and America
Target Spots of Monoclonal Antibody Agents Approved by FDA by May 2012
R&D Fields of Therapeutic Antibody around the Globe, 2004 and 2011
Number of Monoclonal Antibody Agents (Including Clinical) Approved by FDA by May 2012
Sales of Monoclonal Antibody Agents Worldwide, 2009-2012
M&A Events Related to Monoclonal Antibody Worldwide (as of 2011)
Time to Market and Annual Sales of Major Monoclonal Antibody Agents around the Globe, 2010-2011
R&D Investment of Major Biopharmaceutical Companies Worldwide, 2009-2011
Expiration Date of Major Monoclonal Antibody Patents Worldwide
Competitive Analysis of Enbrel on American and Canadian Market
Several Cooperative Projects of Monoclonal Antibody Enterprises around the Globe, 2011-2012
Monoclonal Antibody Industrial Bases in China
Monoclonal Antibody Agents Approved in China as of December 2012
Technological Level Comparison of Monoclonal Antibody Agents at Home and Abroad
Sales of Monoclonal Antibody Agents in China, 2010-2012
Purchase Amount of Major Monoclonal Antibody Agents in Typical Hospitals of 22 Cities in China, 2009-2011
Purchase Amount of Rituximab in Sample Hospitals of China and YoY Growth, 2008-2011
Purchase Amount of Rituximab in Typical Hospitals of Three Major Cities in China, 2009-2011
Purchase Amount of Trastuzumab in Sample Hospitals of China, 2010-2011
Purchase Amount of Trastuzumab in Typical Hospitals of Three Major Cities in China, 2009-2011
Purchase Amount of Cetuximab in Sample Hospitals of China, 2010-2011
Sales Condition of Cetuximab/Erbitux in China, 2009-2011
Purchase Amount of Infilixmab in Hospitals of Three Major Cities in China, 2010-2011
Purchase Amount of Etanercept in Sample Hospitals of China and YoY Growth, 2009-2011
Purchase Amount of Etanercept in Hospitals of Three Major Cities in China, 2010-2011
Price Comparison of Yisaipu, Qiangke and Enbrel (Recombinant Human TNF Receptor-Ig Fusion Protein for Injection)
Death Causes Composition of Rural Residents in China, 2010
Monoclonal Antibody Products Accessing Local Medical Insurance in China
Several Monoclonal Antibody Products under Research in China (as of the end of 2011)
Listed Companies Investing in Monoclonal Antibody Industry in China, 2009-2012
Major M&A Cases of Roche, 1990-2010
Revenue and Operating Income of Roche, 2008-2012
Revenue of Roche by Business, 2010-2012
Revenue of Roche’s Pharmaceutical Business by Application, 2010-2011
Revenue of Roche by Region, 2010-2011
Revenue of Roche’s Pharmaceutical Business by Region, 2010-2012
R&D Investment of Roche by Business and % in Revenue, 2011
Sales of Roche’s (Genentech) Major Monoclonal Antibody Products Worldwide, 2010-2011
Sales of Roche’s Monoclonal Antibody Products by Region, 2010-2011
Investment of Roche in China
Sales Condition of Roche’s Rituximab in China, 2009-2011
Sales Condition of Roche’s Trastuzumab in China, 2009-2011
Revenue and Net Income of Johnson & Johnson, 2008-2011
Revenue Structure of Johnson & Johnson by Product, 2011
R&D Investment of Johnson & Johnson and % in Revenue, 2009-2011
Monoclonal Antibody Products of Johnson & Johnson
Sales of Johnson & Johnson’s Infliximab Worldwide, 2009-2011
Enterprises in China and Major Products of Johnson & Johnson
Import Value of Infliximab in China, 2010-2011
Revenue and Net Income of Merck, 2008-2011
Revenue of Merck by Product, Q3 2011 and Q3 2012
R&D Investment of Merck and % in Revenue, 2009-2011
Sales Condition of Cetuximab/Erbitux in China, 2009-2011
Revenue and Net Income of NVS, 2008-2012
Revenue Structure of NVS by Business, 2011
R&D Investment of NVS and % in Revenue, 2009-2011
NVS’s Monoclonal Antibody Products and Sales, 2011
Development History of NVS’s Pharmaceutical Business in China
Revenue of AbbVie by Product or Region, 2009-2011
R&D Investment of AbbVie, 2009-2011
Monoclonal Antibody Products and Sales of AbbVie, 2011
Global Sales of Adalimumab, 2007-2011
Revenue and Net Income of Amgen, 2008-2012
Revenue of Amgen by Product, 2009-2011
Revenue of Amgen by Region, 2009-2011
R&D Investment of Amgen and % in Revenue, 2008-2011
Product Lines of Amgen by the end of 2011
Marketized Monoclonal Antibody Products of Amgen (As of February 2012)
Revenue of Amgen’s Monoclonal Antibody Products for Sale, 2009-2011
Status Quo of Amgen’s Several Monoclonal Antibody Products under Research (As of February 2012)
Revenue of Amgen’s Enbrel by Region, 2009-2011
Patent Term of Enbrel
Revenue of Panitumumab by Region, 2009-2011
Patent Term of Panitumumab
Revenue of Amgen’s Denosumab by Region, 2010-2011
Revenue and Net Income of CP Guojian, 2008-2010
Several Monoclonal Antibody Products of CP Guojian under Research (As of June 2012)
Several Monoclonal Antibody Products of Zhangjiang Biotech under Research
Several Monoclonal Antibody Products of Biotech Pharmaceutical under Research
Revenue and Total Profit of Huasun Group, 2007-2010
Revenue of Huasun Biotech, 2007-2011
Revenue and Profit of Hisun Pharmaceutical, 2008-2012
Revenue and Profit of Walvax Biotechnology, 2007-2012
Monoclonal Antibody Technical Indicators of Shanghai Fengmao
R&D Progress of Shanghai Fengmao’s Five Monoclonal Antibody Generic Drugs (As of August 2012)
Revenue and Total Profit of Fosun Pharmaceutical, 2008-2012
Revenue and Operating Income of SL Pharmaceutical, 2007-2012

  • China Commercial Vehicle Industry
    Commercial vehicle are usually large trucks, buses or vans used to transport people,  goods and material. China is one of the nations that contributes to over 50% of commercial vehicle production. The industry has grown in leaps and bounds over the couple of years. Even though the growth rates aren’t as impressive as two years [...]
  • The Prospective Market of Drug Eluting Stents
    Drug Eluting Stents are the recent development that’s are now being used frequently for curing narrowed coronary arteries. These stents help to keep the artery open and supply drugs at regular intervals preventing any further obstruction. The stents are usually small scaffolds of wire and are placed in the artery. This has been a welcome [...]
  • Anaesthesia Machine Industry is Flourishing due to an Extensive Customer Base with Therapeutic Needs
    The Anaesthesia Machine Industry comprises of the manufacturers and users of Anaesthesia Machines which are basically workstations or units that assist a person to administer Anaesthesia on the other. It includes plug & play Anaesthesia delivery units (ADUs). The industry also comprises of the various accessories like monitors and information systems and support services involved [...]
  • The Need for an Electric Cars Boosts The Lithium Sulfate Market
    Lithium is a highly demanded material. The popularity of this metal is primarily due to the characteristics of this metal and its compounds. Some of the characteristics of this material are that it has the highest electrochemical potential of all metals, a very high co-efficient of thermal expansion, acting as a viscosity modifier in melts, [...]
  • Tire Roller Industry
    Tire roller is one of the most popular equipment used in the construction industry. A tire roller offers multiple services from building highways, industrial sites, binder courses, wear courses and many more. Tire rollers come with different features like easy adjustment of tyres, flexible ballast, oscillating tires, etc. that facilitates in doing a particular work. [...]
  • The Oil Drilling Rig Industry
  • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and …

  • HER2-Negative Breast Cancer’s Therapeutic Market
  • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can cure …

  • The Market of Plate Heat Exchanger
  • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitations …

  • The Industry of Binding Machines
  • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the …

  • The Boom In Women Infertility Market
  • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Abatacept – Comprehensive patent search
    Published: 16-Apr-2015        Price: US $9300 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Eculizumab – Comprehensive patent search
    Published: 16-Apr-2015        Price: US $9300 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Rituximab – Comprehensive patent search
    Published: 16-Apr-2015        Price: US $9300 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Antibody Deals and Alliances of 2014
    Published: 1-Mar-2015        Price: US $1495 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." The Antibody Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014. Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced wo......
  • Monoclonal Antibodies Partnering Terms and Agreements
    Published: 1-Feb-2015        Price: US $2995 Onwards        Pages: 1071
    The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest monoclonal antibody deals announced in the healthcare secto......
  • Ustekinumab – Comprehensive patent search
    Published: 20-Jan-2015        Price: US $9300 Onwards        
    Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are the benchmark in comprehensive, accurate and relevant patent data. Searched and analysed by highly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on you......
  • Antibody Partnering Terms and Agreements
    Published: 1-Jan-2015        Price: US $2995 Onwards        Pages: 1625
    The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. The......
  • Crescendo Biologics Limited – Product Pipeline Review – 2014
    Published: 24-Dec-2014        Price: US $1500 Onwards        Pages: 20
    Global Markets Direct's, ‘Crescendo Biologics Limited Product Pipeline Review 2014', provides an overview of the Crescendo Biologics Limited's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Crescendo Biologics Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It al......
  • Monoclonal Antibody Markets in China
    Published: 1-Dec-2014        Price: US $4000 Onwards        Pages: 188
    China's demand for Monoclonal Antibody has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity,......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs